Results 151 to 160 of about 97,023 (309)

Incidence and Characteristics of HBV Reactivation‐Related Events Following HBsAg Seroclearance: Long‐Term Follow‐up of a Population‐Based Cohort in Japan

Hepatology Research, EarlyView.
In a population‐based cohort in Japan, HBV reactivation‐related events were observed after HBsAg seroclearance, including one virologically confirmed hepatic flare occurring spontaneously without chemotherapy or immunosuppression. These findings indicate that HBsAg seroclearance does not always represent complete viral eradication, supporting the need ...
Kazumi Yamasaki, Satoshi Shirahama, Takahiro Yasaka, Shota Yamaguchi, Masashi Mizokami, Junko Tanaka, Hiroaki Okamoto, Hiroshi Yatsuhashi   +7 more
wiley   +1 more source

PREVALENCE OF HEPATITIS B INFECTION IN MARRIED WOMEN OF CHILD BEARING AGE IN DISTRICT ISLAMABAD

Gomal Journal of Medical Sciences, 2014
Background: Mother to infant transmission of hepatitis B virus (HBV) represents a major factor in maintaining chronic infection and depends on the degree of maternal infectivity status.
Najma Javed, Sumera Naz
doaj  

Hepatitis B Surface Antigen Neutralization [PDF]

, 2020
openaire   +1 more source

Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI

Hepatology Research, EarlyView.
Hepatocellular carcinoma (HCC) is a common type of liver cancer. Recently, combination therapy with atezolizumab plus bevacizumab has become a standard systemic treatment for patients with unresectable HCC. Some HCCs show high signal intensity on the hepatobiliary phase of Gd‐EOB‐DTPA–enhanced MRI.
Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masakatsu Tsurusaki, Keitaro Sofue, Yoshihiko Yano, Hidenori Toyoda, Atsushi Hiraoka, Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki, Norio Itokawa, Masanori Atsukawa, Kazuhito Kawata, Kazuto Tajiri, Joji Tani, Toru Ishikawa, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Takashi Kumada, Naoshi Nishida, Yuzo Kodama   +24 more
wiley   +1 more source

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

Hepatology Research, EarlyView.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami, Soranobu Ninomiya, Takayasu Ideta, Ayumu Kanbe, Toshihide Maeda, Daisuke Minowa, Daisuke Taguchi, Masaya Kubota, Hiroyasu Sakai, Kenji Imai, Yasuko Yamamoto, Hiroyasu Ito, Kuniaki Saito, Osamu Yoshida, Yoichi Hiasa, Masahito Shimizu   +15 more
wiley   +1 more source

[Controversy and consensus on antiviral treatment strategies for low-level hepatitis B surface antigens]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Hou YH, Zhang LY.
europepmc   +1 more source

Updated Burden and Long‐Term Projections of Chronic Hepatitis B and C in Japan: A Nationwide Markov Modeling Study

Hepatology Research, EarlyView.
ABSTRACT Aim Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major causes of liver‐related morbidity and mortality worldwide. Although Japan has implemented nationwide screening and treatment programs for decades, updated nationwide estimates and long‐term projections are limited.
Junko Tanaka, Akemi Kurisu, Ko Ko, Aya Sugiyama, Tomoyuki Akita   +4 more
wiley   +1 more source

Harnessing conserved epitopes and multivalent antigen strategies for vaccine design: Lessons learned and opportunities. [PDF]

Hum Vaccin Immunother
Adjei-Gati E, Quaye CNO, Lamptey PO, Oklu LD, Kwofie JN, Hafiz YA, Kusi KA.   +6 more
europepmc   +1 more source

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

Hepatology Research, EarlyView.
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka   +2 more
wiley   +1 more source

A review of adult and pediatric post-transplant liver pathology. [PDF]

, 1987
Demetris, AJ, Jaffe, R, Starzl, TE
core